Aminopyrimidine inhibitors of tyrosine kinase

• US 10,568,965 B2
• Filed: 04/21/2014
• Issued: 02/25/2020
• Est. Priority Date: 06/09/2009
• Status: Active Grant

• Current Assignee: Auspex Pharmaceuticals, Inc. (Teva Pharmaceutical Industries Limited)
• Original Assignee: Auspex Pharmaceuticals, Inc. (Teva Pharmaceutical Industries Limited)
• Inventors: Zhang, Chengzhi
• Primary Examiner(s): West, Theodore R.
• Application Number:
  US14/257,347
• Publication Number:
  US 20140227260A1
• Time in Patent Office: 2,136 Days
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07D 401/14 containing three or more hetero rings

Abstract

The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.

Claims

1. A compound that is:

2. The compound as recited in claim 1, wherein said pharmaceutically acceptable salt is a hydrochloride monohydrate.

3. The compound as recited in claim 1, wherein at least one position designated as D has deuterium enrichment of no less than about 50%.

4. The compound as recited in claim 1, wherein at least one position designated as D has deuterium enrichment of no less than about 90%.

5. The compound as recited in claim 1, wherein at least one position designated as D has deuterium enrichment of no less than about 98%.

6. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method of treating a tyrosine kinase-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

8. The method as recited in claim 7, wherein said disorder is chronic phase Philadelphia chromosome positive chronic myelogenous leukemia, accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia, gastrointestinal stromal cancer, or melanoma.

9. The method as recited in claim 7, further comprising administering to the subject an additional therapeutic agent.

10. The method as recited in claim 9, wherein said additional therapeutic agent is an alkylating agent, an anti-metabolite agent, a mitotic inhibitor, a tyrosine kinase inhibitor, a topoisomerase inhibitor, a cancer immunotherapy monoclonal antibody, an anti-tumor antibiotic agent, or an anti-cancer agent.

11. The method as recited in claim 10, wherein said alkylating agent is chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, or uramustine.

12. The method as recited in claim 10, wherein said anti-metabolite agent is aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine or gemcitabine.

13. The method as recited in claim 10, wherein said mitotic inhibitor is docetaxel, paclitaxel, vinblastine, vincristine, vindesine, or vinorelbine.

14. The method as recited in claim 10, wherein said tyrosine kinase inhibitor is dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, or sunitinib.

15. The method as recited in claim 10, wherein said topoisomerase inhibitor is etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, or irinotecan.

16. The method as recited in claim 10, wherein said cancer immunotherapy monoclonal antibody is rituximab, alemtuzumab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.

17. The method as recited in claim 10 wherein said anti-tumor antibiotic agent is daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, or hydroxyurea.

18. The method as recited in claim 10, wherein said anti-cancer agent is amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, or anagrelide.

19. The method as recited in claim 7, further resulting in at least one effect that is:

decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;

increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

or

an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

20. The method as recited in claim 7, further resulting in at least two effects that are:

decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;

increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and

an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

21. The method as recited in claim 7, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

22. The method as recited in claim 21, wherein the cytochrome P450 isoform is CYP2C8, CYP2C9, CYP2C19, or CYP2D6.

23. The method as recited claim 7, wherein the method effects a decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

24. The method as recited in claim 23, wherein said cytochrome P450 or monoamine oxidase isoform is CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, or MAOB.

25. The method as recited in claim 7, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

26. The method as recited in claim 25, wherein the diagnostic hepatobiliary function endpoint is alanine aminotransferase (“

ALT”

), serum glutamic-pyruvic transaminase (“

SGPT”

), aspartate aminotransferase (“

AST,”

“

SGOT”

), ALT/AST ratios, serum aldolase, alkaline phosphatase (“

ALP”

), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“

GGTP,”

“

γ

-GTP,”

“

GGT”

), leucine aminopeptidase (“

LAP”

), liver biopsy, liver ultrasonography, liver nuclear scan, 5′

-nucleotidase, or blood protein.